Indegene , a digital-first life sciences commercialization company, has announced the launch of NEXT Medical Writing Automation, an advanced platform that combines deep medical writing expertise with generative AI (GenAI) technology. This innovative tool aims to streamline complex medical writing workflows across clinical development, regulatory submissions, and beyond.

Revolutionizing Medical Writing

NEXT Medical Writing Automation is designed to address the challenges faced by medical writing teams, who are often under pressure to deliver precise, regulatory-ready documents within tight deadlines. The platform operates within familiar environments like Microsoft Word, auto-generating compliant drafts that adapt to diverse sponsor formats and workflows.

Key Features and Benefits

• Integration with Existing Systems: NEXT seamlessly integrates with Regulatory Information Management (RIM) systems, maintaining traceability and consistency across documents.
• Efficiency Boost: The platform offers automated scheduling, intelligent task assignments, and robust data flow integration, helping life sciences organizations scale operations efficiently.
• Compliance Focus: While enhancing efficiency, NEXT maintains a strong compliance backbone, crucial in an environment of growing document requirements and increased scrutiny.

Leveraging Cortex AI Engine

At the heart of NEXT is Indegene's Cortex AI engine, a life sciences-specialist knowledge engineering and multi-agent orchestration platform. Cortex enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance.

Industry Impact

Sameer Lal, SVP, Enterprise Medical Solutions at Indegene, commented on the launch: "We see this platform as more than automation—it's about elevating the entire practice of medical writing. Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting."

About Indegene

Indegene Limited is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech, and medical device companies develop products, get them to market, and grow their impact through the life cycle in a more effective, efficient, and modern way.

The launch of NEXT Medical Writing Automation reinforces Indegene's commitment to building AI-driven, domain-first solutions that help life sciences organizations modernize critical processes and meet business objectives with confidence.

For more information about Indegene and its services, visit www.indegene.com .

In a notable market development, Indegene Ltd. witnessed a substantial block trade on the National Stock Exchange (NSE), signaling potential investor interest in the company's shares.

Block Trade Details

A significant block trade of approximately 1,804,900 shares of Indegene Ltd. was executed on the NSE. The transaction occurred at a price of ₹590.80 per share, resulting in a total trade value of ₹106.63 crore.

Market Implications

Block trades of this magnitude often attract attention from market participants as they can indicate:

• Institutional investor activity
• Potential changes in ownership structure
• Market sentiment towards the stock

While the identities of the buyers and sellers in block trades are typically not disclosed, such transactions can sometimes lead to speculation about the motivations behind the trade.

About Indegene Ltd.

Indegene Ltd. is a technology-led healthcare solutions provider that combines deep industry expertise with fit-for-purpose technology in delivering IP-driven digital transformation for healthcare organizations. The company's services span clinical, medical, and commercial functions of life sciences and healthcare organizations.

Investors and market analysts will likely be watching closely to see if this block trade leads to any noticeable impact on Indegene's stock price or trading volume in the coming days. As always, market participants are advised to conduct their own research and consider their individual investment goals before making any investment decisions based on this information.